KSCP stock price is currently consolidating near $3.12, with intraday highs testing $3.20 resistance. Technical charts show the RSI approaching 65, signaling moderate bullish momentum. Investors are closely monitoring sector ETF movements, which can often front-run individual stock action in this category. Instead, what we have here is a radiation oncology specialist. Focusing on an advanced form of brachytherapy, Vivos utilizes radioactive materials (yttrium-90) to directly implement a high-dose treatment to the target area while imposing a minimal dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, which should see a 7.1% CAGR to land at a value of $1.62 billion by 2030 . Our team is working diligently to resolve the issue. Thank you for your patience and understanding. Analysts note that breaking above the 200-day moving average of $3.15 could shift mid-term trend projections bullish, especially if sector momentum continues in the defense and security vertical.